Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

835 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L; RE-LY Investigators. Reilly PA, et al. Among authors: wallentin l. J Am Coll Cardiol. 2014 Feb 4;63(4):321-8. doi: 10.1016/j.jacc.2013.07.104. Epub 2013 Sep 27. J Am Coll Cardiol. 2014. PMID: 24076487 Free article. Clinical Trial.
Aborted myocardial infarction in patients with ST-segment elevation: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy.
Taher T, Fu Y, Wagner GS, Goodman SG, Fresco C, Granger CB, Wallentin L, van de Werf F, Verheugt F, Armstrong PW. Taher T, et al. Among authors: wallentin l. J Am Coll Cardiol. 2004 Jul 7;44(1):38-43. doi: 10.1016/j.jacc.2004.03.041. J Am Coll Cardiol. 2004. PMID: 15234403 Free article. Clinical Trial.
Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3).
Curtis JP, Alexander JH, Huang Y, Wallentin L, Verheugt FW, Armstrong PW, Krumholz HM, Van de Werf F, Danays T, Cheeks M, Granger CB; ASSENT-2 and ASSENT-3 Investigators. Curtis JP, et al. Among authors: wallentin l. Am J Cardiol. 2004 Aug 1;94(3):279-83. doi: 10.1016/j.amjcard.2004.04.019. Am J Cardiol. 2004. PMID: 15276088
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes.
MICHELANGELO OASIS 5 Steering Committee; Mehta SR, Yusuf S, Granger CB, Wallentin L, Peters RJ, Bassand JP, Budaj A, Joyner C, Chrolavicius S, Fox KA. MICHELANGELO OASIS 5 Steering Committee, et al. Among authors: wallentin l. Am Heart J. 2005 Dec;150(6):1107. doi: 10.1016/j.ahj.2005.09.025. Am Heart J. 2005. PMID: 16338245 Clinical Trial.
Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy).
James SK, Lindahl B, Timmer JR, Ottervanger JP, Siegbahn A, Stridsberg M, Armstrong P, Califf R, Wallentin L, Simoons ML. James SK, et al. Among authors: wallentin l. Am J Cardiol. 2006 Jan 15;97(2):167-72. doi: 10.1016/j.amjcard.2005.08.036. Epub 2005 Nov 21. Am J Cardiol. 2006. PMID: 16442356
Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators; Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, et al. Among authors: wallentin l. N Engl J Med. 2006 Apr 6;354(14):1464-76. doi: 10.1056/NEJMoa055443. Epub 2006 Mar 14. N Engl J Med. 2006. PMID: 16537663 Free article. Clinical Trial.
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.
Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA; OASIS-6 Trial Group. Yusuf S, et al. Among authors: wallentin l. JAMA. 2006 Apr 5;295(13):1519-30. doi: 10.1001/jama.295.13.joc60038. Epub 2006 Mar 14. JAMA. 2006. PMID: 16537725 Clinical Trial.
Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy.
James SK, Lindbäck J, Tilly J, Siegbahn A, Venge P, Armstrong P, Califf R, Simoons ML, Wallentin L, Lindahl B. James SK, et al. Among authors: wallentin l. J Am Coll Cardiol. 2006 Sep 19;48(6):1146-54. doi: 10.1016/j.jacc.2006.05.056. Epub 2006 Aug 28. J Am Coll Cardiol. 2006. PMID: 16978997 Free article. Clinical Trial.
835 results